Ton Rabelink
Overview
Explore the profile of Ton Rabelink including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
393
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van Schaik M, Arends E, Wetzels M, Kraaij T, Verbruggen S, van der Kooij S, et al.
Lupus Sci Med
. 2025 Feb;
12(1).
PMID: 39939125
Objective: Combination therapy with rituximab and belimumab is a novel treatment strategy for severe SLE and lupus nephritis. Phase II studies have shown promising results, although long-term data are currently...
2.
Novoa J, Westra I, Steeneveld E, Neves N, Daleman L, Asensio A, et al.
Cytotherapy
. 2024 May;
26(9):1105-1117.
PMID: 38703154
One of the challenges in Good Manufacturing Practice (GMP)-compliant human induced pluripotent stem cell (hiPSC) production is the validation of quality control (QC) tests specific for hiPSCs, which are required...
3.
van Leeuwen J, Hafemann S, van der Boog P, van der Woude D, Rabelink T, Teng Y
Clin Kidney J
. 2023 Dec;
16(12):2754-2756.
PMID: 38045999
No abstract available.
4.
van Leeuwen J, Penne E, Rabelink T, Knevel R, Teng Y
Comput Biol Med
. 2023 Dec;
168:107757.
PMID: 38039893
Background: Because anti-neutrophil cytoplasmatic antibody (ANCA)-associated vasculitis (AAV) is a rare, life-threatening, auto-immune disease, conducting research is difficult but essential. A long-lasting challenge is to identify rare AAV patients within...
5.
Dirikgil E, van Leeuwen J, Bredewold O, Ray A, Jonker J, Soonawala D, et al.
BMJ Open
. 2022 Sep;
12(9):e061339.
PMID: 36130755
Introduction: Both rituximab (RTX) and cyclophosphamide (CYC) are effectively used in combination with steroids as remission induction therapy for patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Several studies have...
6.
7.
Chatzikyrkou C, Menne J, Izzo J, Viberti G, Rabelink T, Ruilope L, et al.
J Hypertens
. 2017 Oct;
35(12):2501-2509.
PMID: 29035939
Aim: It is important to know which factors predict the development of microalbuminuria in patients with diabetes mellitus type II. Material: Data from the Randomized Olmesartan and Diabetes Microalbuminuria Prevention...
8.
Cantelmo A, Conradi L, Brajic A, Goveia J, Kalucka J, Pircher A, et al.
Cancer Cell
. 2016 Nov;
30(6):968-985.
PMID: 27866851
Abnormal tumor vessels promote metastasis and impair chemotherapy. Hence, tumor vessel normalization (TVN) is emerging as an anti-cancer treatment. Here, we show that tumor endothelial cells (ECs) have a hyper-glycolytic...
9.
Bredewold O, De Fijter J, Rabelink T
NDT Plus
. 2015 May;
4(3):170-2.
PMID: 25984148
A 38-year-old male was admitted with fever, progressive jaundice, cervical lymphadenopathy, hepatomegaly and acute oliguric renal failure. Epstein-Barr virus (EBV) infection was diagnosed by detection of EBV-DNA in plasma and...
10.
Dane M, van den Berg B, Rabelink T
Atherosclerosis
. 2014 May;
235(1):56-7.
PMID: 24816037
No abstract available.